Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Prasinezumab Humanized Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA542174
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets alpha-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson's disease pathology. Prasinezumab targets alpha-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with alpha-synuclein misfolding and/or its transmission.
Specifications
Prasinezumab Humanized | |
Recombinant Monoclonal | |
Unconjugated | |
PRX002; RG-7935 | |
Human SNCA. | |
100 μg | |
Primary | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid | |
Chemical |
ELISA, SDS-Page | |
1.64 mg/mL | |
PBS with no preservative; pH 7.4 | |
Human | |
Protein A/G | |
RUO | |
Human | |
Antibody | |
IgG1 κ |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction